Articles related to DISEASE-MODIFYING THERAPIES (DMTs)

Blarcamesine (Anavex 2-73), an investigational once-daily oral autophagy enhancer, showed sustained cognitive, functional, and brain volume benefits through nearly 3 years in a Phase 2b/3 trial and open-label extension presented at AD/PD 2026.

A GLP-1 receptor agonist delivered directly into the knee joint received FDA Fast Track designation for osteoarthritis with synovitis, with phase 2a data not expected until 2027.

A 9-member Delphi panel just issued 65 implementation recommendations for anti-amyloid mAbs in private practice. Here’s what counts as practice-shaping and what’s still consensus opinion.

Researchers are increasingly studying peripheral biomarkers in high-risk populations to improve diagnosis and prediction, with standard therapies currently limited to temporary symptom relief.

“A 65% reduction in the risk of death and a statistically significant extension in median survival of over 14 months represent a clinically meaningful benefit of notable magnitude in ALS.” — Alon Ben-Noon, CEO, Neurosense Therapeutics

“Fenebrutinib represents the first potential scientific breakthrough for the PPMS community in over a decade.” — Levi Garraway, MD, PhD, Roche Chief Medical Officer